SCHEMBL1923959

SCHEMBL1923959

COC(=O)c1ccc(N2CCNC(C)C2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
XIAP P98170 1/20 0.47
BIRC2 Q13490 1/20 0.47
HPGD P15428 2/20 0.43
ALOX15 P16050 1/20 0.43
MGLL Q99685 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MAPT P10636 3/20 0.43
HDAC1 Q13547 1/20 0.42
ADRB1 P08588 1/20 0.42
FGFR1 P11362 1/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GRM2 Q14416 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4417772 1.00 ALDH1A1 (0.54) ALDH1A1XIAPBIRC2HPGDALOX15
SCHEMBL4420179 1.00 ALDH1A1 (0.54) ALDH1A1XIAPBIRC2HPGDALOX15
SCHEMBL27634785 0.86 ALDH1A1 (0.51) ALDH1A1HPGDALOX15MGLLHSD17B10
SCHEMBL28510427 0.86 ALDH1A1 (0.51) ALDH1A1HPGDALOX15MGLLHSD17B10
SCHEMBL7658796 0.85 HTT (0.50) ALDH1A1HPGDTSHRSMN1; SMN2RAB9A
SCHEMBL7655528 0.85 HTT (0.50) ALDH1A1HPGDTSHRSMN1; SMN2RAB9A
SCHEMBL7657843 0.85 HTT (0.50) ALDH1A1HPGDTSHRSMN1; SMN2RAB9A
SCHEMBL1922775 0.84 USP2 (0.58) ALDH1A1HPGDHSD17B10MAPTHDAC1
SCHEMBL22802008 0.84 NPC1 (0.47) ALDH1A1HSD17B10MAPTHDAC1ADRB1
SCHEMBL3770299 0.84 NPC1 (0.47) ALDH1A1HSD17B10MAPTHDAC1ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102971291-A Novel amide derivative and use thereof as medicine MITSUBISHI TANABE PHARMA CORP 2013-03-13 CN disclosed
CN-102123989-A Pyrazole compounds 436 ASTRAZENECA AB 2011-07-13 CN disclosed
EP-2328872-A1 PYRAZOLE COMPOUNDS 436 AstraZeneca AB (SE) 2011-06-08 EP disclosed
US-20090318468-A1 PYRAZOLE COMPOUNDS 436 ASTRAZENECA AB (SE) 2009-12-24 US disclosed
WO-2009153592-A1 PYRAZOLE COMPOUNDS 436 ASTRAZENECA AB (SE) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318468-A1 PYRAZOLE COMPOUNDS 436 CYP3A43, CYP3A7, CYP3A4 ALDH1A1 283/4885XIAP 2432/4885BIRC2 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.